Loading...
OTCM
KANT
Market cap3mUSD
Jun 10, Last price  
0.27USD
Name

Kineta Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
0.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
109.34%
Rev. gr., 5y
13.89%
Revenues
5m
+178.65%
4,312,0008,384,0005,341,0002,840,0005,000,00010,488,0009,091,0001,953,0005,442,000
Net income
-14m
L-77.64%
-25,040,000-37,232,000-59,432,000-61,832,000-59,125,000-13,877,000-11,960,000-63,067,000-14,099,000
CFO
-16m
L-14.82%
-19,415,000-41,925,000-52,395,000-58,844,000-52,166,0002,296,000-17,853,000-19,029,000-16,209,000
Dividend
Dec 19, 20221.43 USD/sh
Earnings
Aug 06, 2025

Profile

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
URL
https://kinetabio.com/
IPO date
Feb 11, 2016
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,442
178.65%
1,953
-78.52%
Cost of revenue
21,165
44,218
Unusual Expense (Income)
NOPBT
(15,723)
(42,265)
NOPBT Margin
Operating Taxes
23
(386)
Tax Rate
NOPAT
(15,746)
(41,879)
Net income
(14,099)
-77.64%
(63,067)
427.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,561
8,988
BB yield
-21.34%
-28.73%
Debt
Debt current
1,714
883
Long-term debt
697
2,891
Deferred revenue
Other long-term liabilities
Net debt
(3,447)
(9,494)
Cash flow
Cash from operating activities
(16,209)
(19,029)
CAPEX
(71)
Cash from investing activities
331
9,270
Cash from financing activities
8,468
11,808
FCF
(14,758)
(41,278)
Balance
Cash
5,858
13,143
Long term investments
125
Excess cash
5,586
13,170
Stockholders' equity
(165,610)
(151,536)
Invested Capital
170,533
158,367
ROIC
ROCE
EV
Common stock shares outstanding
11,054
4,926
Price
3.63
-42.83%
6.35
 
Market cap
40,126
28.28%
31,280
 
EV
36,848
21,932
EBITDA
(15,714)
(42,192)
EV/EBITDA
Interest
337
3,737
Interest/NOPBT